Estudio de prefactibilidad de producción porcina sostenible en la zona de La mojana sucreña, Municipio De Majagual.

Desarrollar el estudio de prefactibilidad para la producción porcina sostenible en la zona de la mojanaEl proyecto de prefactibilidad tiene un norte y va dirigido a resolver problemáticas técnicas, económicas y medioambientales, en principio se procura identificar cuáles son los problemas que hacen compleja una explotación porcina, identificando factores que limitan a los productores pequeños en la mayoría de los casos a ejercer de una de las actividades que por tradición se desarrollan en Colombia y en esta zona de la Mojana. Identificamos el primero, recursos tanto económicos para adaptar y acondicionar la infraestructura, como de manejo en este caso agua. El segundo factor es el tipo de alimento que normalmente se utiliza para este tipo de explotación y por último el manejo, tanto de los residuos sólidos como líquidos evitando así el uso abundante de agua y el control medioambiental de olores contaminantes. Ahora bien, ya que el estudio se basa en el análisis de las explotaciones de la zona e incluso el país, buscamos encontrar cuales son las alternativas que procuren resolver o mitigar el impacto que genera cada una de estas variables y llevar a las explotaciones Porcicola al máximo desempeño, haciéndola más sostenible y procurando el éxito de la rentabilidad que es menor costo, mayor utilidad. En primer lugar, la infraestructura convencional genera grandes gastos tanto en manejo como en agua, cosa que se convierte en un problema, la alternativa para mejorar esto sería la cama profunda, una alternativa atractiva ya que su mayor ventaja es el reciclaje de desechos de industrias agrícolas y el bajo consumo de agua.The prefeasibility project has a north and is aimed at solving technical, economic and environmental problems, in principle it is sought to identify what are the problems that make a pig farm complex, identifying factors that limit small producers in most cases to exercise one of the activities that by tradition are developed in Colombia and in this area of La Mojana. We identify the first, both economic resources to adapt and condition the infrastructure, as in this case water management. The second factor is the type of food that is normally used for this type of exploitation and finally the handling of both solid and liquid waste, thus avoiding the abundant use of water and the environmental control of polluting odors. Now, since the study is based on the analysis of farms in the area and even the country, we seek to find which are the alternatives that seek to solve or mitigate the impact generated by each of these variables and take Porcicola farms to maximum performance, making it more sustainable and ensuring the success of profitability that is lower cost, more useful. First, the conventional infrastructure generates large costs in both management and water, which becomes a problem, the alternative to improve this would be the deep bed, an attractive alternative since its greatest advantage is the recycling of industrial waste agricultural and low water consumption. In the matter of food we find that the greatest expense that a Porcicola activity can generate is in the food and if we obtain the way to generate crops that, although they do not completely replace the protein quality of the concentrated food, it is a supplement that improves the quality of the final product that is meat and decrease investment in food. Together these two elements make the Porcicola project more profitable and therefore increases the feasibility of its execution

Estudio de prefactibilidad de producción porcina sostenible en la zona de La mojana sucreña, Municipio De Majagual.

Desarrollar el estudio de prefactibilidad para la producción porcina sostenible en la zona de la mojanaEl proyecto de prefactibilidad tiene un norte y va dirigido a resolver problemáticas técnicas, económicas y medioambientales, en principio se procura identificar cuáles son los problemas que hacen compleja una explotación porcina, identificando factores que limitan a los productores pequeños en la mayoría de los casos a ejercer de una de las actividades que por tradición se desarrollan en Colombia y en esta zona de la Mojana. Identificamos el primero, recursos tanto económicos para adaptar y acondicionar la infraestructura, como de manejo en este caso agua. El segundo factor es el tipo de alimento que normalmente se utiliza para este tipo de explotación y por último el manejo, tanto de los residuos sólidos como líquidos evitando así el uso abundante de agua y el control medioambiental de olores contaminantes. Ahora bien, ya que el estudio se basa en el análisis de las explotaciones de la zona e incluso el país, buscamos encontrar cuales son las alternativas que procuren resolver o mitigar el impacto que genera cada una de estas variables y llevar a las explotaciones Porcicola al máximo desempeño, haciéndola más sostenible y procurando el éxito de la rentabilidad que es menor costo, mayor utilidad. En primer lugar, la infraestructura convencional genera grandes gastos tanto en manejo como en agua, cosa que se convierte en un problema, la alternativa para mejorar esto sería la cama profunda, una alternativa atractiva ya que su mayor ventaja es el reciclaje de desechos de industrias agrícolas y el bajo consumo de agua.The prefeasibility project has a north and is aimed at solving technical, economic and environmental problems, in principle it is sought to identify what are the problems that make a pig farm complex, identifying factors that limit small producers in most cases to exercise one of the activities that by tradition are developed in Colombia and in this area of La Mojana. We identify the first, both economic resources to adapt and condition the infrastructure, as in this case water management. The second factor is the type of food that is normally used for this type of exploitation and finally the handling of both solid and liquid waste, thus avoiding the abundant use of water and the environmental control of polluting odors. Now, since the study is based on the analysis of farms in the area and even the country, we seek to find which are the alternatives that seek to solve or mitigate the impact generated by each of these variables and take Porcicola farms to maximum performance, making it more sustainable and ensuring the success of profitability that is lower cost, more useful. First, the conventional infrastructure generates large costs in both management and water, which becomes a problem, the alternative to improve this would be the deep bed, an attractive alternative since its greatest advantage is the recycling of industrial waste agricultural and low water consumption. In the matter of food we find that the greatest expense that a Porcicola activity can generate is in the food and if we obtain the way to generate crops that, although they do not completely replace the protein quality of the concentrated food, it is a supplement that improves the quality of the final product that is meat and decrease investment in food. Together these two elements make the Porcicola project more profitable and therefore increases the feasibility of its execution

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Search for narrow resonances using the dijet mass spectrum in pp collisions at s√=8 TeV

Results are presented of a search for the production of new particles decaying to pairs of partons (quarks, antiquarks, or gluons), in the dijet mass spectrum in proton-proton collisions at s√=8  TeV. The data sample corresponds to an integrated luminosity of 4.0  fb−1, collected with the CMS detector at the LHC in 2012. No significant evidence for narrow resonance production is observed. Upper limits are set at the 95% confidence level on the production cross section of hypothetical new particles decaying to quark-quark, quark-gluon, or gluon-gluon final states. These limits are then translated into lower limits on the masses of new resonances in specific scenarios of physics beyond the standard model. The limits reach up to 4.8 TeV, depending on the model, and extend previous exclusions from similar searches performed at lower collision energies. For the first time mass limits are set for the Randall–Sundrum graviton model in the dijet channel

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN